You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
…melanoma response. Blood markers: LDH and ctDNA are discussed but currently not reliable for routine monitoring in melanoma. Biopsy: Occasionally…
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
…melanoma response. Blood markers: LDH and ctDNA are discussed but currently not reliable for routine monitoring in melanoma. Biopsy: Occasionally…
,
Worried Your Immunotherapy Isn’t Working: The Role of Imaging and ctDNA
…2. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2025. Melanoma: Cutaneous. 2025:1-246. 3. Goel N, Ward WH, Yu JQ et…
In Plain English: The Results of DreamSeq
…targeted therapy and initial treatment with immunotherapy. BRAF Mutant Melanoma There are actually several types of BRAF mutation in melanoma…
,
In Plain English—COVID-19, the vaccines, and melanoma: What do melanoma patients and their families need to know?
…know about the vaccines? What do we know about COVID infection in patients with melanoma and other cancers? What do…
,
Genetic Testing Performed in Melanoma
…melanoma? MS: The most commonly altered gene in melanoma-prone families is CDKN2A—about 20-30% of US families with familial melanoma carry…
,
Genetic Testing Performed in Melanoma
…melanoma, but melanoma is often not the predominant cancer type in these individuals/families. Why does the gene POT1 matter with…
,
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
…Options The Future of Melanoma Treatment in 2026 The Future of Melanoma Treatment in 2026 webinar has just been recorded…
,
After Melanoma, A Good Life Gets Even Better
…Bob also participates in AIM’s Steps Against Melanoma to raise awareness and funding for melanoma research, education, prevention, early detection,…
,
Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans
…compared with nonveterans (9.0% vs 2.9%) and a higher prevalence of melanoma history (2.2% vs 0.6%).1 Immunotherapy has been shown…
,
AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University
…14, 2019 (San Rafael, California) AIM at Melanoma and AIM at Melanoma Research Foundation announce the opening of the third…
,
,
Recent Posts
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026